The FDA is moving toward earlier access to psychedelic medicines, but agency officials and mental health experts pressed for concrete safety guardrails around dosing, monitoring, and provider qualifications. At a public hearing, commenters urged the agency to require credentials for psychedelic providers as it accelerates psychedelic therapy development. A separate FDA-focused discussion highlighted how regulators could structure an initial approval pathway while issues like redosing durability and maintenance regimens are still being refined. The FDA’s approach is centered on translating trial findings into practical, continuously studied use in the real world. For sponsors, the key near-term risk is not only efficacy signal durability, but the operational requirements that will come with any initial green light—patient selection, longitudinal follow-up, and the clinical infrastructure needed to administer and evaluate psychedelic treatments safely.